Publication: 4441

Publication: 4441

10 Year Follow-up of CALGB 10603/RATIFY: Midostaurin Versus Placebo Plus Intensive Chemotherapy in Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia Patients Aged 18-60 Years

DOI

URL

Google Scholar

Citation:: Blood vol 144 (Supplement 1) 218

Meeting Instance:: ASH 2024
Year:: 2024
Type:: Abstract
Sub type:: Oral
Funding:: NCTN
Endpoint:: Primary
Analysis:: Long-Term-Followup
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: epreprint

Note:

Methodological:: No
Biospecimen:: No
SDC:: No

Parents:: None
Children:: None

Program:: OGC
Primary Committee:: Leukemia
Sec. Committees:

Pharmas:: Novartis
Grants:: U10CA180821, U10CA180882

Corr. Author:
Authors:: Richard Stone Jun Yin Ilene Galinsky Richard A. Larson Hartmut Dohner Axel Benner Maral Saadati Sumithra J. Mandrekar Ben L. Sanford Susan M. Geyer Thomas Prior Rebecca B. Klisovic Hubert Serve Sergio Amadori Bruno Medeiros Richard F. Schlenk Andrew H. Wei Christian Thiede Konstanze Döhner Guido Marcucci Jorge Sierra Miguel A. Sanz Joseph Brandwein Theo J.M. de Witte Frederick R. Appelbaum Martin S. Tallman Jürgen Krauter Arnold Ganser Gerhard Ehninger Dietger W. Niederwieser

Networks:: CA043, LAPS-IL036, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-OH007

Study: CALGB-10603
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords: